In a regulatory filing, Vertex Pharmaceuticals CMO Carmen Bozic disclosed the sale of 2,280 common shares of the company on May 29 at a price of $445.56 per share.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VRTX:
- Vertex Pharmaceuticals sees Q1 capex $20M-$205M
- Vertex’s High-Stakes Acquisition: Navigating the Uncertainties of the Alpine Deal
- Biotech Alert: Searches spiking for these stocks today
- Vertex Pharmaceuticals price target raised to $477 from $466 at UBS
- Vertex Pharmaceuticals price target raised to $529 from $511 at Leerink